Cypress Capital’s Ginkgo Bioworks DNA Stock Holding History

Cypress Capital’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-45	Closed	-$602	–	156
2024 Q2	$602	Buy	+45	New	+$1.34K	﹤0.01%	347

Other funds holding DNA

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Cypress Capital's DNA Position: Q3 2024 in Review

Cypress Capital sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 45 shares — an estimated $602 sold.

Cypress Capital first reported a position in DNA in Q2 2024 and held it in 1 quarter. The position peaked at $602 in Q2 2024. 158 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

Cypress Capital reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
Cypress Capital sold 45 Ginkgo Bioworks shares in Q3 2024, an estimated $602.
Cypress Capital first reported a position in Ginkgo Bioworks in Q2 2024 and held it in 1 quarter.
Cypress Capital's Ginkgo Bioworks position peaked at $602 in Q2 2024.
158 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Cypress Capital's 13F filing for Q3 2024, filed 12 Nov 2024.